CASP8 D302H and meningioma risk: an analysis of five case-control series.
Bethke, L; Sullivan, K; Webb, E
; Murray, A; Schoemaker, M; Auvinen, A; Kiuru, A; Salminen, T; Johansen, C; Christensen, HC; +12 more...Muir, K; McKinney, P; Hepworth, S; Dimitropoulou, P; Lophatananon, A; Feychting, M; Lönn, S; Ahlbom, A; Malmer, B; Henriksson, R; Swerdlow, A; Houlston, R and
(2009)
CASP8 D302H and meningioma risk: an analysis of five case-control series.
Cancer letters, 273 (2).
pp. 312-315.
ISSN 0304-3835
DOI: 10.1016/j.canlet.2008.08.010
; Murray, A; Schoemaker, M; Auvinen, A; Kiuru, A; Salminen, T; Johansen, C; Christensen, HC; +12 more...Muir, K; McKinney, P; Hepworth, S; Dimitropoulou, P; Lophatananon, A; Feychting, M; Lönn, S; Ahlbom, A; Malmer, B; Henriksson, R; Swerdlow, A; Houlston, R and
(2009)
CASP8 D302H and meningioma risk: an analysis of five case-control series.
Cancer letters, 273 (2).
pp. 312-315.
ISSN 0304-3835
DOI: 10.1016/j.canlet.2008.08.010
Caspase 8 (CASP8) is a key regulator of apoptosis or programmed cell death, and hence a defence against cancer. The CASP8 polymorphism D302H has recently been shown to influence the risk of breast cancer. We tested the hypothesis that the CASP8 polymorphism D302H may influence risk of meningioma through analysis of five independent series of case patients and controls (n=631 and 637, respectively). Carrier status for 302H was not associated with a statistically significantly increased risk (OR=1.16; 95% CI: 0.87-1.53; P=0.31) making it unlikely that this variant contributes to the inherited risk of meningioma.
Full text not available from this repository.
Downloads